Your browser doesn't support javascript.
loading
An evaluation of mirikizumab for the treatment of ulcerative colitis.
White, Christopher; Irving, Peter M.
Affiliation
  • White C; Department of Gastroenterology, St Thomas' Hospital, London, UK.
  • Irving PM; Department of Gastroenterology, St Thomas' Hospital, London, UK.
Expert Opin Biol Ther ; : 1-8, 2024 Oct 16.
Article in En | MEDLINE | ID: mdl-39360778
ABSTRACT

INTRODUCTION:

Treatment of ulcerative colitis (UC) aims to reduce symptoms and complications by decreasing intestinal inflammation. A proportion of patients do not respond to, do not tolerate, or are inappropriate candidates for current therapies. Interleukin (IL)-23 is a therapeutic target and mirikizumabis the first p19-targeted IL-23 antibody approved for the treatment of moderately to severely active UC. AREAS COVERED This review summarizes the pro-inflammatory effects of IL-23 and outlines the pharmacokinetics of mirikizumab. It provides a synopsis of the available phase II and phase III evidence for the efficacy and safety of mirikizumab in UC. EXPERT OPINION The mirikizumab clinical development program demonstrated its superiority over placebo and its favorable safety profile in the treatment of UC. Its positioning in therapeutic algorithms remains to be fully understood but mirikizumab has proven efficacy in both advanced therapy (AT)-naïve and AT-experienced patients. The inclusion in the license of extended induction for non-responders as well as rescue intravenous dosing allows for flexibility in patient with limited primary response and secondary loss of response.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Expert Opin Biol Ther Journal subject: BIOLOGIA / TERAPEUTICA Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Expert Opin Biol Ther Journal subject: BIOLOGIA / TERAPEUTICA Year: 2024 Document type: Article Country of publication: